No­var­tis is­n't mak­ing deals in Chi­na just for the sake of buy­ing there.

That's the word from CEO Vas Narasimhan, who told re­porters on a...

The Broad In­sti­tute of MIT and Har­vard is team­ing up with Boston Chil­dren’s Hos­pi­tal and The Jack­son Lab­o­ra­to­ry to launch a new cen­ter fo­cused on...

Agios said it is drop­ping a next-gen­er­a­tion sick­le cell dis­ease drug af­ter lack­lus­ter re­sults from a mid-stage tri­al.

The drug, known as tebapi­vat, rep­re­sent­ed Agios’ sec­ond...

Gilead and Mer­ck’s HIV da­ta: The duo will presentmore de­tailed re­sults of the Phase 3 tri­als of their once-week­ly oral HIV treat­ment reg­i­men at...